Other

Sigmund E Lasker

Toshiyuki Arai

Pradeep M Gupte

Compositions containing silver ammonium phenytoin complex and a phenytoin are usefully employed, particularly when applied topically, for the treatment of animal or human tissue, for wound healing and are useful in wound dressing preparations for the prevention or treatment of infections. The compositions are usefully applied by direct topical application to the wound or tissue to be treated or may be directly applied to the wound or tissue or incorporated in or coated on a dressing, such as a bandage.

Composition containing silver ammonium phenytoin complex and a phenytoin

Stable, organometallic complexes of 5,5-diphenyl-2,4 imidazolidenedione (diphenyl hydantoin) are versatile biocides, effective when applied topically or parenterally to animal tissue, and when applied topically to plants. The diphenyl Hydantoin complexes are seen to prevent animal and plant tissue infections, and may be combined with other materials to inhibit infection.

Organometallic diphenyl hydrantoins and uses thereof

The present invention provides a process for visualizing tissue metabolism in a subject comprising injecting .sup.17 O.sub.2 into the peritoneal cavity of a subject and detecting formed H.sub.2.sup.17 O in tissues of the subject. The .sup.17 O.sub.2 is injected as a gas or as microbubbles formed from an aqueous protein solution.

Process for visualizing tissue metabolism using oxygen-17

Organometallic diphenyl hydantoin

A diagnostic imaging agent is provided for use in conjunction with a magnetic resonance imaging system for the imaging of spacial oxygen distribution in tissue. The imaging agent is comprised of a complex of oxygen-17, a biologically acceptable liquid carrier, such as a perfluorinated compound, and an emulsifying agent, and wherein the agent has an average particle size of less than about 0.6 microns, and an ionic composition essentially equal to that of blood. Useful information can be obtained, and in certain instances, therapy administered, by a non-envasive imaging technique relative to tissue perfusion by .sup.19 F-NMR (imaging of .sup.19 F) and oxygen utilization by .sup.1 H-NMR (imaging of H.sub.2.sup.17 O as a metabolite).

Method for introducing oxygen-17 into tissue for imaging in a magnetic

The object of the invention is to provide a new antithrombotic agent. Coagulation of blood acts through a cascade of stages, the mechanisms and interaction of which have not been fully clarified. The present invention provides a derivative of heparin which can be administered orally, topically, or parenterally to antagonize the effect of factor Xa to a greater extent than commercial porcine heparin. In addition, the derivative has insignificant USP anticoagulant and platelet aggregating activities. The heparin derivative according to the invention, has a molecular weight of from about 2,500 to about 4,000 daltons, gives a positive metachromatic test for sulfated polysaccharides. Preferably, when isolated as the sodium salt, the derivative contains by elemental analysis about 26.2% carbon, 4.33% hydrogen, 1.98% nitrogen, 7.1% sulfur, and 9.8% sodium, the molar ratio C:N:S:Na being about 10:1.5:2:4.

Growing community of inventors

New York, NY, United States of America

Sigmund E Lasker